Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp66455_8k.htm |
Exhibit 99.1
Press Release www.shire.com |
 |
Holding(s) in Company
June 10, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)
| 1.
Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii |
Shire plc |
| 2 Reason for the notification (please tick the appropriate box or boxes): | |
| An acquisition or disposal of voting rights | |
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |
| An event changing the breakdown of voting rights | X |
| Other (please specify): |
| 3.
Full name of person(s) subject to the notification obligation: iii |
Deutsche Bank AG |
| 4.
Full name of shareholder(s) (if different from 3.):iv |
Deutsche Bank AG, London Branch
|
| 5.
Date of the transaction and date on which the threshold is crossed or reached: v |
07/06/2016 |
| 6. Date on which issuer notified: | 09/06/2016 |
| 7.
Threshold(s) that is/are crossed or reached: vi, vii |
Below notifiable threshold |
| 8. Notified details: | |||||||
| A: Voting rights attached to shares viii, ix | |||||||
Class/type of
|
Situation
previous to the triggering transaction |
Resulting situation after the triggering transaction | |||||
| Number of Shares |
Number of Voting Rights |
Number of shares |
Number
of voting rights |
% of voting rights x | |||
| Direct | Direct xi | Indirect xii | Direct | Indirect | |||
| JE00B2QKY057 | 28,378,378 | 28,378,378 | Below notifiable threshold |
Below notifiable threshold |
0 | Below notifiable threshold |
0 |
| B: Qualifying Financial Instruments | ||||
| Resulting situation after the triggering transaction | ||||
| Type
of financial instrument |
Expiration date xiii |
Exercise/
Conversion Period xiv |
Number
of voting rights that may be acquired if the instrument is exercised/ converted. |
%
of voting rights |
| ||||
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||
| Resulting situation after the triggering transaction | ||||||
| Type
of financial instrument |
Exercise price | Expiration date xvii | Exercise/ Conversion period xviii |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
| |
| Nominal | Delta | |||||
| Total (A+B+C) | |
| Number of voting rights | Percentage of voting rights |
| Below notifiable threshold | Below notifiable threshold |
| 9.
Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi | |
| |
| Proxy Voting: | |
| 10. Name of the proxy holder: | |
| 11.
Number of voting rights proxy holder will cease to hold: |
|
| 12.
Date on which proxy holder will cease to hold voting rights: |
|
13. Additional information: |
|
| 14. Contact name: | Stacy Otieno |
| 15. Contact telephone number: | 02075476268 |
For further information please contact:
| Investor Relations | ||
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We have best-in-class products available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com